

# THINKING OUTSIDE THE BOX FOR TARGET IDENTIFICATION AND VALIDATION FOR OBESITY AND TYPE II DIABETES TREATMENT

**Itzik Harosh<sup>1</sup> and Marco Ciufolini<sup>2</sup>**

<sup>1</sup>ObeTherapy, France

<sup>2</sup>University of British Columbia, British Columbia

**M**any obesity related genes have been proposed as targets for the treatment of obesity and type II diabetes. However, these obesity genes did not provide efficient drug therapy mainly due to the redundancy of the biochemical pathway involved in obesity and the lack of specificity and the lack of association of the gene target and the lean phenotype. It is therefore a challenge to identify crucial gene(s) targets involved in energy metabolism associated with "lean or starvation phenotype". Congenital enteropeptidase deficiency is an extremely rare pathology which answers all the criteria. We have identified several lead compounds that are active in vitro against the enteropeptidase and shows very promising results in a mouse model that will be discussed

iharosh@obetherapy.com